【Product for Licensing】Better Clinical Compound for Pulmonary IPF & PPF & ILD

If interested, please contact DrugTimes BD Team at BD@drugtimes.cn

【Product for Licensing】Better Clinical Compound for Pulmonary IPF & PPF & ILD
【Superior potency】

  • Superior potency compared to Pirfenidone,15-fold increase in TNF-α inhibition, and good bioactivity in TGF-β 
  • PhII blind data show good efficacy in clinical

【Better Safety】

  • Large Safety Window
  • Good safety & tolerability in clinical PhIa, PhIb, and ongoing PhII
  • Long-term GLP Tox: 26- week rat GLP study completed, 39-week in dog completed, both support long-term clinical usage with ideal therapeutic window

【Favorable Administration】

  • 150mg bid,300mg daily

【Lower Risk for Photo-Tox】

  • No Photo-Tox concern in non-clinical and clinical

【CMC】

  • API process ready & scalable for NDA, Drug product tablet formulation and process well developed
  • Lower COGs

【IP Protection】

  • Patents secured till 2037+

【Rights for licensing】

  • Ex-China rights or Global rights

【Contact info】

发布者:DrugTimes001,转载请首先联系contact@drugtimes.cn获得授权

(0)
打赏 为好文打赏 支持药时代 共创新未来! 为好文打赏 支持药时代 共创新未来!
上一篇 2024年7月2日 13:47
下一篇 2024年7月2日 14:39

相关推荐

公众号
公众号
分享本页
返回顶部
世界肝炎日特别活动:人源动力,肝研新篇 点击这里了解详情